Topical Amitriptyline 1% Gel for the Treatment of Burning Mouth Syndrome

CompletedOBSERVATIONAL
Enrollment

30

Participants

Timeline

Start Date

January 2, 2024

Primary Completion Date

November 30, 2024

Study Completion Date

May 30, 2025

Conditions
Burning Mouth SyndromeStomatodynia
Interventions
DRUG

Topical amitriptyline 1% gel

Patients diagnosed with burning mouth syndrome received topical amitriptyline 1% gel applied intraorally. The gel was instructed to be placed on the oral mucosa (tongue and/or other symptomatic areas) two times per day for several weeks, without swallowing. Treatment was provided as part of routine clinical care. This retrospective study collected data on pain intensity, patient global impression of improvement, and adverse events to evaluate the real-world effectiveness and tolerability of this topical formulation.

Trial Locations (1)

30008

Clinica Odontologica Universitaria, Murcia

All Listed Sponsors
lead

Universidad de Murcia

OTHER

NCT07214181 - Topical Amitriptyline 1% Gel for the Treatment of Burning Mouth Syndrome | Biotech Hunter | Biotech Hunter